GlassScriptPhysician profile
Clement S Rose
NPI 1346238177
$2,980.21
in general payments reported to CMS, 2019-2025
23 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $264 · 2021: $486 · 2022: $638 · 2023: $365 · 2024: $292 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $686.14 | 2019-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $634.07 | 2019-2025 | Biktarvy |
| Lilly USA, LLC | $224.99 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $206.44 | 2021-2025 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $161.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $109.70 | 2019-2024 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $106.63 | 2021-2022 | |
| Amgen INC. | $104.24 | 2019-2024 | Repatha, Krystexxa |
| Exact Sciences Corporation | $103.02 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $81.74 | 2019-2022 | |
| Pfizer INC. | $77.74 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.57 | 2023-2025 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $57.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $54.30 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Watermark Medical, INC. | $47.61 | 2022 | |
| Mylan Specialty L.P. | $35.04 | 2020 | |
| Dexcom, INC. | $32.36 | 2020-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $24.57 | 2019 | |
| Astellas Pharma US INC | $23.49 | 2019 | |
| Seagen INC. | $16.84 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.64 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.